Kymera Therapeutics, Inc.
Clinical trials sponsored by Kymera Therapeutics, Inc., explained in plain language.
A clinical-stage biotech developing targeted protein degradation drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug KT-579 enters first human tests – no disease, just safety check Results expected Dec 2026 (estimated)
- Three pill versions of one drug go head to head in the bloodstream Results expected Apr 2027 (estimated)
- New pill shows promise for severe eczema sufferers Results expected Jun 2027 (estimated)
-
New asthma pill shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…
Phase 2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Oral asthma drug KT-621 tested for Long-Term safety
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of an oral drug called KT-621 in people with asthma. Participants have already completed a previous KT-621 asthma study. The goal is to see how well the drug works over time and if any side effects appear with longer use.
Phase 2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Three pill versions of one drug go head to head in the bloodstream
Knowledge-focused Recruiting nowResearchers are comparing three oral formulations of an experimental drug called KT-621 to see how much of each version reaches the bloodstream. The study enrolls 54 healthy adults who take the different formulations in sequence, with blood samples measuring drug levels over time…
Phase 1 • Sponsor: Kymera Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New drug KT-579 enters first human tests – no disease, just safety check
Knowledge-focused Recruiting nowThis early-stage study is testing a new oral drug, KT-579, in 96 healthy adults to see if it is safe and how the body handles it. Participants receive either the drug or a placebo. The goal is to gather safety data, not to treat any disease.
Phase 1 • Sponsor: Kymera Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC